Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Aytu BioPharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Medomie will commercialize Adzenys XR-ODT (amphetamine) and Cotempla XR-ODT (methylphenidate) in Israel and the Palestinian Authority.
Brand Name : Adzenys XR
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 31, 2023
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Aytu BioPharma
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?